Výsledky vyhledávání - "Cellerant Therapeutics Inc."

News

Cellerant Therapeutics, Inc. Presents Additional Phase 2 Results Showing Romyelocel-L Reduces Risk of Infections in AML Patients Undergoing High Dose Ara-C-Based (HiDAC) Induction Chemotherapy

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 11/29/2018.

Zobrazit plný text záznamu

Plný text ve formátu HTML

News

Cellerant Therapeutics, Inc. Publishes Preclinical Data Highlighting Potential of its CLL1-Targeting Antibody-Drug Conjugate to Treat Acute Myeloid Leukemia

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 07/23/2018.

Zobrazit plný text záznamu

Plný text ve formátu HTML

News

Cellerant Therapeutics, Inc. Announces FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation for Romyelocel-L to Prevent Infections During Neutropenia

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 07/02/2018.

Zobrazit plný text záznamu

Plný text ve formátu HTML

News

Cellerant Therapeutics, Inc. Presents Phase 2 Results Showing CLT-008 Significantly Reduces Risk of Infections in AML Patients Undergoing Standard Induction Chemotherapy

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 06/18/2018.

Zobrazit plný text záznamu

Plný text ve formátu HTML

News

Cellerant Therapeutics, Inc. CLT-008 Phase 2 Results Show Significant Reduction in Infections and Days in Hospital in Severely Neutropenic AML Patients

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 06/04/2018.

Zobrazit plný text záznamu

Plný text ve formátu HTML

News

Cellerant Therapeutics, Inc. to Present Results of Phase 2 Clinical Trial of CLT-008 at American Society of Clinical Oncology (ASCO) 2018 Annual Meeting and European Hematology Association (EHA) 23rd Congress

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 05/17/2018.

Zobrazit plný text záznamu

Plný text ve formátu HTML

News

Cellerant Therapeutics, Inc. Awarded $6.86 Million Grant From California Institute for Regenerative Medicine to Support Development of Novel Antibody-Drug Conjugate for AML

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 08/22/2017.

Zobrazit plný text záznamu

Plný text ve formátu HTML

News

Cellerant Therapeutics, Inc. Presents Preclinical Data Showing Promise of a Novel Differentiated Target on Leukemic Stem Cells

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 10/11/2016.

Zobrazit plný text záznamu

Plný text ve formátu HTML

News

Cellerant Therapeutics, Inc. Awarded $1.5 Million SBIR Contract for Development of Novel Antibody-Based Therapeutic Against IL1RAP

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 09/26/2016.

Zobrazit plný text záznamu

Plný text ve formátu HTML

News

Cellerant Therapeutics Announces Timothy Fong as Vice President of Cellular Technologies and Jagath Reddy Junutula as Vice President of Antibody Discovery & Development

Autor: Cellerant Therapeutics, Inc.

Publikováno v: Business Wire (English). 05/12/2014.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání